Home  /  Resource Library  /  PATIENT REPORTED OUTCOMES FROM BRUIN CLL-321: A RANDOMIZED PHASE 3 TRIAL COMPARING PIRTOBRUTINIB TO IDELALISIB/RITUXIMAB OR BENDAMUSTINE/RITUXIMAB IN COVALENT BTKI PRETREATED CLL/SLL

PATIENT REPORTED OUTCOMES FROM BRUIN CLL-321: A RANDOMIZED PHASE 3 TRIAL COMPARING PIRTOBRUTINIB TO IDELALISIB/RITUXIMAB OR BENDAMUSTINE/RITUXIMAB IN COVALENT BTKI PRETREATED CLL/SLL

EHA 2025